Bioceres Crop Solutions (BIOX)
NASDAQ:BIOX
Top Page
Bioceres Crop Solutions
(NASDAQ:BIOX)
Select Model
Select Model
Rating:42Neutral
Price Target:
$0.52
▲(17.73% Upside)
Action:ReiteratedDate:04/03/26
The score is held down primarily by sharply weakened profitability and higher leverage, which reduce financial flexibility. Technicals also point to a pressured longer-term trend with negative momentum. Improved operating and free cash flow provides some support but is not enough to offset the scale of losses and balance-sheet risk, while valuation is difficult to judge due to negative earnings and no dividend data.
Positive Factors
Strong free cash flow
Sustained positive operating and free cash flow provides a durable liquidity buffer to fund R&D, working capital and restructuring without immediate equity raises. Strong FCF growth improves the company’s ability to service obligations and invest in commercial rollouts over the medium term.
Negative Factors
Elevated leverage
Substantially higher leverage materially reduces financial flexibility and raises refinancing risk, especially in cyclical agriculture markets. A thin equity cushion versus assets increases the likelihood of covenant pressure, forced asset sales or costly refinancing during adverse conditions.
Read all positive and negative factors
Positive Factors
Negative Factors
Strong free cash flow
Sustained positive operating and free cash flow provides a durable liquidity buffer to fund R&D, working capital and restructuring without immediate equity raises. Strong FCF growth improves the company’s ability to service obligations and invest in commercial rollouts over the medium term.
Read all positive factors
Bioceres Crop Solutions (BIOX) vs. SPDR S&P 500 ETF (SPY)
Market Cap
$34.16M
Dividend YieldN/A
Average Volume (3M)1.08M
Price to Earnings (P/E)―
Beta (1Y)0.99
Revenue Growth-27.90%
EPS Growth-4194.67%
CountryUS
Employees400
SectorBasic Materials
Sector Strength58
IndustryAgricultural Inputs
Share Statistics
EPS (TTM)-0.06
Shares Outstanding63,228,237
10 Day Avg. Volume1,709,433
30 Day Avg. Volume1,077,044
Financial Highlights & Ratios
PEG Ratio<0.01
Price to Book (P/B)1.07
Price to Sales (P/S)0.85
P/FCF Ratio8.00
Enterprise Value/Market Cap7.69
Enterprise Value/Revenue0.92
Enterprise Value/Gross Profit2.48
Enterprise Value/Ebitda21.73
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)-0.16
Revenue Forecast (FY)$307.10M
Bioceres Crop Solutions Business Overview & Revenue Model
Company Description
Bioceres Crop Solutions Corp., together with its subsidiaries, provides crop productivity solutions. It operates through three segments: Seed and Integrated Products, Crop Protection, and Crop Nutrition. The Seed and Integrated Products segment de...
How the Company Makes Money
Bioceres Crop Solutions makes money primarily by selling and licensing agricultural inputs and technologies. Key revenue streams include: (1) Seeds and integrated traits: revenue from the commercialization of proprietary seeds and trait technologi...
Bioceres Crop Solutions Key Performance Indicators (KPIs)
Any
Revenue by Segment
Shows how much revenue each business segment contributes, highlighting areas of strength and potential growth within Bioceres Crop Solutions' diverse operations.
Shows how much revenue each business segment contributes, highlighting areas of strength and potential growth within Bioceres Crop Solutions' diverse operations.
Data provided by:
The Fly
The FlyBioceres Crop Solutions Earnings Call Summary
Earnings Call Date:Nov 12, 2025
(Q1-2026)
| % Change Since: |
Next Earnings Date:May 07, 2026
Earnings Call Sentiment Neutral
The earnings call presented a mixed picture with notable improvements in gross margin and adjusted EBITDA, supported by cost reductions. However, these were counterbalanced by significant declines in revenue across multiple segments and an ongoing debt dispute. The company is focusing on building a more resilient and profitable model despite a complex operating environment.Positive Updates
Gross Margin Expansion
Gross margin expanded significantly by 650 basis points to 47% compared to 40% in the same quarter last year, reflecting improved product mix and margin expansion.
Negative Updates
Decline in Total Revenues
Total revenues for the quarter were $77.5 million, a 17% decline from the same period last year, primarily due to strategic transitions and sales timing effects in Latin America.
Read all updates
Q1-2026 Updates
Positive
Negative
Gross Margin Expansion
Gross margin expanded significantly by 650 basis points to 47% compared to 40% in the same quarter last year, reflecting improved product mix and margin expansion.
Read all positive updates
Company Guidance
During the Bioceres Crop Solutions Fiscal First Quarter 2026 earnings call, Federico Trucco, CEO, highlighted key financial metrics and strategic priorities. Despite a 17% decline in total revenues to $77.5 million, the company achieved a gross profit of $36 million, maintaining a robust gross margin expansion of 650 basis points to 47%. The company's adjusted EBITDA surged 61% to $13.6 million, driven by a $5.9 million reduction in operating costs. Bioceres is focused on maintaining a gross margin above 40%, reducing annual SG&A by $10-12 million, and achieving profitability with adjusted EBITDA above 20% of sales. The company also reported a significant decline in revenues from Crop Protection and Seed and Integrated Products segments, but noted improvements in cost efficiency and product mix. Current debt was reported at $188.7 million, with a net financial debt of $225.9 million, while the net debt to adjusted EBITDA ratio improved to 6.8x. The company is committed to operating with discipline, focusing on profitability, liquidity, and capital efficiency amid a challenging environment.Bioceres Crop Solutions Financial Statement Overview
Summary
Income Statement
22
Negative
Balance Sheet
33
Negative
Cash Flow
58
Neutral
| Breakdown | TTM | Jun 2025 | Jun 2024 | Jun 2023 | Jun 2022 | Jun 2021 |
|---|---|---|---|---|---|---|
Income Statement | ||||||
| Total Revenue | 285.11M | 333.30M | 464.83M | 419.45M | 328.46M | 206.70M |
| Gross Profit | 105.70M | 130.20M | 181.59M | 180.25M | 126.44M | 90.88M |
| EBITDA | 12.08M | 13.59M | 55.45M | 72.38M | 47.91M | 43.70M |
| Net Income | -235.97M | -51.80M | 3.24M | 18.78M | -7.20M | -6.87M |
Balance Sheet | ||||||
| Total Assets | 560.36M | 763.65M | 852.55M | 818.06M | 518.22M | 394.59M |
| Cash, Cash Equivalents and Short-Term Investments | 12.58M | 34.74M | 56.17M | 60.05M | 38.61M | 46.78M |
| Total Debt | 239.46M | 276.61M | 270.95M | 257.41M | 169.79M | 174.58M |
| Total Liabilities | 453.75M | 468.43M | 501.17M | 487.56M | 359.92M | 304.30M |
| Stockholders Equity | 73.77M | 262.81M | 315.30M | 298.85M | 127.61M | 67.74M |
Cash Flow | ||||||
| Free Cash Flow | 71.76M | 35.30M | 18.93M | -19.97M | -26.51M | -20.13M |
| Operating Cash Flow | 78.02M | 49.91M | 41.72M | 2.59M | -17.52M | -6.21M |
| Investing Cash Flow | -5.08M | -6.13M | -28.73M | -25.73M | 2.90M | -8.31M |
| Financing Cash Flow | -78.11M | -50.71M | -10.06M | 32.95M | 14.82M | 7.36M |
Bioceres Crop Solutions Technical Analysis
Neutral
0.44
Price Trends
0.60
Negative
1.05
Negative
1.93
Negative
Market Momentum
-0.04
Negative
54.40
Neutral
91.66
Negative
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For BIOX, the sentiment is Neutral. The current price of 0.44 is below the 20-day moving average (MA) of 0.46, below the 50-day MA of 0.60, and below the 200-day MA of 1.93, indicating a neutral trend. The MACD of -0.04 indicates Negative momentum. The RSI at 54.40 is Neutral, neither overbought nor oversold. The STOCH value of 91.66 is Negative, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Neutral sentiment for BIOX.
Bioceres Crop Solutions Risk Analysis
Bioceres Crop Solutions disclosed 68 risk factors in its most recent earnings report. Bioceres Crop Solutions reported the most risks in the "Finance & Corporate" category.
Finance & Corporate - Financial and accounting risks. Risks related to the execution of corporate activity and strategy
Latest Risks Added 3 New Risks
1.
Certain of the Rizobacter shares we own are subject to a judicial injunction that, if decided unfavorably to us, would require us to surrender part of our interest in Rizobacter thereby reducing our equity interest in Rizobacter. Q2, 2024
2.
The disposition or sale of our ordinary shares may be subject to taxation in Argentina. Q2, 2024
3.
Our share repurchase program may reduce liquidity. Q2, 2024
Bioceres Crop Solutions Peers Comparison
UnderperformOutperform
Sector (61)
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
61 Neutral | $10.43B | 7.12 | -0.05% | 2.87% | 2.86% | -36.73% | |
48 Neutral | $96.96M | -8.58 | -158.60% | ― | 45.88% | 43.12% | |
46 Neutral | $14.82M | -1.23 | ― | ― | -21.82% | -104.92% | |
43 Neutral | $69.07M | -2.18 | -22.89% | ― | -4.29% | -276.74% | |
43 Neutral | $2.78M | -1.16 | -80.74% | ― | -1.80% | 15.74% | |
42 Neutral | $34.16M | -0.11 | -105.50% | ― | -27.90% | -4194.67% |
* Basic Materials Sector Average
BIOX
Bioceres Crop Solutions
0.54
-3.43
-86.40%
AVD
American Vanguard
2.42
-1.33
-35.47%
SEED
Origin Agritech
1.22
-0.43
-26.06%
RKDA
Arcadia Biosciences
1.35
-1.43
-51.37%
BHST
BioHarvest Sciences
4.28
-1.32
-23.57%
Bioceres Crop Solutions Corporate Events
Bioceres Crop Solutions Faces Nasdaq Minimum Bid Price Compliance Deadline
Mar 17, 2026
Bioceres Crop Solutions, a Rosario, Argentina-based agbiotech group listed on Nasdaq under the ticker BIOX, develops and commercializes technologies aimed at boosting farm productivity while promoting environmentally friendly practices. Its offeri...
Bioceres Faces Pro Farm Impairment and Going-Concern Doubts as It Refocuses on Core Business
Mar 17, 2026
Bioceres Crop Solutions reported that its second-quarter fiscal 2026 results, for the six months ended December 31, 2025, reflect a tough operating backdrop, including weak commodity prices and tighter credit conditions for Argentine farmers that ...
Bioceres Crop Solutions Files December 2025 Interim Financials With SEC
Mar 13, 2026
On March 13, 2026, Bioceres Crop Solutions filed a Form 6-K with the U.S. Securities and Exchange Commission, providing unaudited interim condensed consolidated financial statements. The filing covers the company’s financial position as of D...
Bioceres Disputes Pro Farm Asset Foreclosure After $15 Million UCC Sale
Jan 20, 2026
On January 20, 2026, Bioceres Crop Solutions reported that a UCC foreclosure sale was held involving collateral pledged by its affiliates Pro Farm Group, Inc. and Pro Farm Michigan Manufacturing, LLC under notes originally issued in August 2022 an...
Bioceres Crop Solutions Calls January 30, 2026 Shareholder Meeting to Approve FY 2025 Accounts and Board Slate
Jan 9, 2026
On January 8, 2026, Bioceres Crop Solutions Corp. filed a Form 6-K announcing that it has convened its 2026 Annual General Meeting of shareholders for January 30, 2026, to be held in New York and accessible virtually. Shareholders of record as of ...
Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.